Quinazoline derivatives viz., Gefitinib(iressa) (Chemical name: 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin)propoxy] and Erlotinib (tarceva) (chemical name: 4-(3-ethynylphenylamino)-6,7-(bis-2-methoxy ethoxy)-quinazoline) are molecules approved recently by US FDA for treatment against locally advanced or metastatic non-small cell lung cancer (NSCLC). These molecules inhibit tyrosine kinase associated with the epiderman growth factor receptor (EGFR-TK) We have developed patent non-infringing routes and protected the processes by filing national and international patents. These processes have several advantages viz., reduction in number of synthetic steps, improvement in yields and more economical. They are ready for commercialization/ technology transfer